Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends



Rating:

Share or cite this content

Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), F. Bonella (Essen, Germany), N. Chaudhuri (Manchester, United Kingdom), F. Varone (Roma, Italy), D. Antin-Ozerkis (New Haven, CT, United States of America), H. Mueller (Biberach, Germany), C. Coeck (Brussels, Belgium), K. Rohr (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France). Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 2538

Member's Comments

No comment yet.

Related content which might interest you: Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 How should we approach the treatment of progressive fibrosing ILDs? Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis Year: 2019 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need Source: Breathe, 16 (3) 200066; 10.1183/20734735.0066-2020 Year: 2020